Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Open-label, Phase I Dose Escalation and Expansion Cohort Study of EOS301984 as Monotherapy and in Combination With Other,Anticancer Treatments in Participants With Advanced Solid Tumors

NCT06547957 is registered in ClinicalTrials.gov with iTeos Therapeutics as lead sponsor.

NCT NCT06547957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06547957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Open-label, Phase I Dose Escalation and Expansion Cohort Study of EOS301984 as Monotherapy and in Combination With Other,Anticancer Treatments in Participants With Advanced Solid Tumors
Lead sponsor
iTeos Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 7, 2023
Completion date
December 31, 2025
Enrollment
55 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors